Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.

Major Japanese firm picks up US drug discovery platform company Jnana in apparent bid to strengthen discovery capabilities and build its mid-stage R&D presence in the renal area. 

It remains extremely challenging to raise money for start-ups in the neuroscience space that still have little data but the commercial possibilities for those investors prepared to take a punt are huge.

With several new drugs progressing for the estimated 70,000 patients in China with DMD, a recent setback for Nippon Shinyaku's contender and progress for Chinese gene therapy developers are adding both uncertainty and likely competition in an untapped market with pressing medical need.